15% OFF USE CODE: SUMMERFREE15 15% OFF USE CODE: SUMMERFREE15 15% OFF USE CODE: SUMMERFREE15 15% OFF USE CODE: SUMMERFREE15 15% OFF
logo with sunset in purple and orange with Reyomi in grey with SR-17018

Frequently Asked
Questions

Key information about SR-17018 for research and analytical purposes.

What is SR-17018?

SR-17018 is a biased G-protein mu-opioid receptor agonist. In pharmacological terms, it preferentially activates the G-protein signaling pathway while minimizing the recruitment of beta-arrestin 2.

In animal models, this “biased” signaling has been shown to provide relief from opioid withdrawal symptoms and potentially reverse opioid tolerance. Because it avoids the beta-arrestin pathway, it is associated with significantly less respiratory depression in preclinical studies compared to traditional opioids like morphine or oxycodone.

No. Research indicates a lack of euphoric or recreational effects.

No. Although data is inconsistent, most reports suggest it does not provide significant analgesic effects in opioid-tolerant subjects.

It is legal for laboratory research purposes only and not approved for human or animal consumption.

The estimated half-life is 8–12 hours, with peak effects occurring approximately 2 hours after administration.

  1. The Skin Test: Open a capsule or take a pinch of powder and mix it with a drop of water to make a paste. Apply a small amount to the inside of your wrist or elbow. Wait 15–30 minutes. If you see redness, itching, or a bump, do not consume the product.
  2. The Lip Test: If the skin test is clear, dab a tiny amount of the powder onto the outer edge of your lip. Wait 15 minutes. If you feel tingling, burning, or swelling, wash it off immediately and do not proceed.

The Micro-Dose: If no reaction occurs, swallow a “micro-dose” (about 1/4 of a capsule or a tiny pinch of powder). Wait 24 hours to monitor for any delayed digestive upset, rashes, or breathing changes before moving to a standard serving.

Research typically begins with a calibration phase at low levels (20–35 mg). Observed benefits appear to reach a plateau at approximately 100 mg.

SR-17018 is insoluble in water and propylene glycol (PG). Due to its chemical structure and solubility profile, it is not suitable for intranasal or intravenous administration. Dosing in studies was done using the “toss and wash” method, chasing each dose with water.

Research Data on Dietary Synergy:

  • Lipid-Enhanced Absorption: It is recommended to administer the research sample alongside fatty foods to improve bioavailability.
  • Inconsistent Food Impact: While food intake generally has an inconsistent impact on the drug’s effects, the absence of food (empty stomach) consistently shows poor efficacy.
  • Investigative Observation: One researcher noted that while individual metabolic responses vary, ensuring the subject has eaten a meal prior to research helps stabilize the onset and duration of the compound’s effects

 

Preclinical studies suggest that SR-17018 may help restore the sensitivity of opioid receptors. However, this poses a severe safety risk. If a person’s tolerance is reduced and they return to their previous dose of a traditional opioid (their “drug of choice”), the risk of a fatal overdose is extremely high.

In harm-reduction communities, two primary methods of transition are often discussed:

  • Direct Transition: Stopping the current opioid and starting SR-17018 immediately.
  • Gradual Transition: Tapering the current opioid while introducing SR-17018 to mitigate withdrawal.

Unlike Buprenorphine (Suboxone), SR-17018 is not reported to cause precipitated withdrawal, meaning it can theoretically be taken while other opioids are still in the system.

Absorption is least effective on an empty stomach.  Fatty foods help the compound metabolize. 

consult a medical professional if you experience:

  • Difficulty breathing or swallowing.
  • Swelling of the tongue or throat.
  • Severe abdominal pain or persistent skin rashes.
Scroll to Top